ESOC 2023, Munich - EVER Symposium

For EVER Pharma our satellite symposium titled ‘Evidence-based therapies for all stroke patients – advances and guideline recommendation’ at the European Stroke Conference 2023 in Munich was very important.

For the first time since ESOC 2019, there was an opportunity to present new evidence, treatment concepts and guideline recommendations at an international conference.

In these years between 2019 and 2023, many new treatment concepts in stroke therapy gained importance, especially thrombectomy. Discussions about pharmacological agents to support recanalization therapies and neurorehabilitation after stroke have also come to the fore. In this period, Cerebrolysin^® has evolved from a recognized drug for motor recovery to a widely accepted standard therapy for ALL stroke patients. The reasons for this were convincingly explained by the three speakers.

Chair: Ales Tomek, Prague (CZ)

• Get with the guidelines in post stroke motor recovery
  Steven Zeiler (US)
• Effective Cerebroprotection in the stroke reperfusion era - why we need it?
  Jacek Staszewski, Warsaw (PL)

Watch also some impressions of the ESOC 2023 in the following video.